Evidence map›Paper›PMID 37670479›Full record

ArticleJournal of veterinary internal medicine

Oral cytarabine ocfosfate pharmacokinetics and assessment of leukocyte biomarkers in normal dogs.

Danielle M Zwueste, Karen M Vernau, William Vernau, Bruno H Pypendop, Heather K Knych, Carlos A Rodrigues, Amir Kol, Maria Questa, Peter J Dickinson

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of veterinary internal medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Danielle M ZwuesteWilliam R. Pritchard Veterinary Medical Teaching Hospital, School of Veterinary Medicine, University of California, Davis, California, USA.
Karen M VernauDepartment of Surgical and Radiological Sciences, University of California Davis, Davis, California, USA.
William VernauDepartment of Pathology, Microbiology and Immunology, University of California Davis, Davis, California, USA.
Bruno H PypendopDepartment of Surgical and Radiological Sciences, University of California Davis, Davis, California, USA.
Heather K KnychK.L. Maddy Equine Analytic Chemistry Laboratory, UC Davis, Davis, California, USA.
Carlos A RodriguesDepartment of Surgical and Radiological Sciences, University of California Davis, Davis, California, USA.
Amir KolDepartment of Pathology, Microbiology and Immunology, University of California Davis, Davis, California, USA.
Maria QuestaDepartment of Pathology, Microbiology and Immunology, University of California Davis, Davis, California, USA.
Peter J DickinsonDepartment of Surgical and Radiological Sciences, University of California Davis, Davis, California, USA.ORCID https://orcid.org/0000-0002-0037-2619
University of California, Davis · USVeterinary Medical Teaching Hospital · US

Funding

Center for Companion Animal Health, University of California, DavisHolliday Neurology Resident Research Grant
6 · The paper itself

Abstract

backgroundCytosine arabinoside (Ara-C) is a nucleoside analog prodrug utilized for immunomodulatory effects mediated by its active metabolite Ara-CTP. Optimal dosing protocols for immunomodulation in dogs have not been defined. Cytarabine ocfosfate (CO) is a lipophilic prodrug of Ara-C that can be administered PO and provides prolonged serum concentrations of Ara-C.

objectivesProvide pharmacokinetic data for orally administered CO and determine accumulation and functional consequences of Ara-CTP within peripheral blood leukocytes. ANIMALS: Three healthy female hound dogs and 1 healthy male Beagle.

methodsProspective study. Dogs received 200 mg/m

resultsMaximum serum concentration (C CONCLUSIONS AND CLINICAL IMPORTANCE: Oral CO may produce prolonged serum Ara-C half-lives at concentrations sufficient to induce functional changes in peripheral leukocytes and is associated with prolonged retention of DNA-incorporated Ara-CTP. Application of functional and active metabolite assessment is feasible and may provide more relevant data to determine optimal dosing regimens for Ara-C-based treatments.

Indexed as

Arabinofuranosylcytosine TriphosphateProdrugsAnimalsArabinonucleotidesBiomarkersChromatography, LiquidCytarabineCytidine MonophosphateDNADogsFemaleLeukocytesMaleProspective StudiesTandem Mass Spectrometry1-arabinofuranosylcytosine-5'-stearylphosphateArabinofuranosylcytosine TriphosphateArabinonucleotidesBiomarkersCytarabineCytidine MonophosphateDNAProdrugsAra-CAra-CTPcanineCytosarHPLCprodrug

Identifiers

PMID37670479
PMCPMC10658504
OpenAlexW4386467029

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.